Oxford Finance

Inhibrx, Inc. is a clinical-stage biotechnology company headquartered in La Jolla, California, that specializes in developing a diverse pipeline of novel biologic therapeutic candidates. The company's focus areas include oncology, orphan diseases, and infectious diseases, employing advanced protein engineering techniques, including its proprietary sdAb platform. Among its leading candidates is INBRX-109, a multivalent agonist of death receptor 5, currently in Phase 1 trials for treating solid tumors, including sarcomas. Another candidate, INBRX-105, serves as an antagonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB, also in Phase 1 trials for PD-L1 expressing tumors. Additional candidates include INBRX-101, aimed at alpha-1 antitrypsin deficiency, and INBRX-103, targeting cluster of differentiation 47. The company's preclinical programs encompass innovative therapies such as INBRX-106, a hexavalent agonist of OX40, and INBRX-111, a multifunctional antibody targeting Pseudomonas aeruginosa. Founded in 2010, Inhibrx has established collaborations with prominent organizations and received funding from various granting agencies.

Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapeutics for rare diseases. The company's primary focus is on its lead candidate, Diazoxide Choline Controlled Release (DCCR), a once-daily oral tablet designed for the treatment of Prader-Willi Syndrome (PWS). DCCR contains diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Currently, the product is being evaluated in a Phase III clinical development program. Established in 1999 and headquartered in Redwood City, California, Soleno Therapeutics was formerly known as Capnia, Inc. before rebranding in May 2017.

Verona Pharma plc is a clinical-stage biopharmaceutical company based in London, dedicated to developing and commercializing innovative therapies for respiratory diseases with significant unmet medical needs. Founded in 2005, the company primarily focuses on its lead product candidate, ensifentrine, an inhaled dual inhibitor of phosphodiesterase enzymes 3 and 4, which functions as both a bronchodilator and an anti-inflammatory agent. Ensifentrine is currently in Phase 2b clinical development as a nebulized formulation for the maintenance treatment of chronic obstructive pulmonary disease (COPD), with additional formulations including a dry powder inhaler and a pressurized metered-dose inhaler also under development. In addition to COPD, Verona Pharma is exploring the use of ensifentrine for other respiratory conditions, including cystic fibrosis and asthma, thereby aiming to enhance the health and quality of life for patients suffering from these chronic disorders.

Headspace is a mental health technology company that provides a digital platform for mindfulness and emotional well‑being. Its mobile app offers guided meditations, sleep aids, and mindfulness programs for work, relationships, and health. The service expands beyond meditation to include clinical content, coaching, therapy, psychiatry, and AI‑driven care navigation, allowing individuals, employees, and health plan members to access personalized support. Headspace partners with organizations to deliver corporate wellness programs that improve employee productivity and well‑being.

Amino Inc. operates an online platform designed to assist users in finding doctors, comparing their qualifications, and booking appointments within the United States. The platform allows patients to search for healthcare providers based on various conditions, procedures, and specialties, thus facilitating informed decisions regarding their healthcare. Established in 2013 and headquartered in San Francisco, California, Amino aims to enhance healthcare financial wellness for companies and their employees by simplifying the navigation of the complex US healthcare system. By leveraging data-driven, individualized care suggestions, the company strives to make high-value healthcare benefits more accessible and intuitive for its users. Formerly known as Pare Labs, Inc., Amino rebranded in May 2014 to better reflect its focus on improving the healthcare experience.

Amino Inc. operates an online platform designed to assist users in finding doctors, comparing their qualifications, and booking appointments within the United States. The platform allows patients to search for healthcare providers based on various conditions, procedures, and specialties, thus facilitating informed decisions regarding their healthcare. Established in 2013 and headquartered in San Francisco, California, Amino aims to enhance healthcare financial wellness for companies and their employees by simplifying the navigation of the complex US healthcare system. By leveraging data-driven, individualized care suggestions, the company strives to make high-value healthcare benefits more accessible and intuitive for its users. Formerly known as Pare Labs, Inc., Amino rebranded in May 2014 to better reflect its focus on improving the healthcare experience.

Pearl Street Dental Management is a dental practice management company operating primarily in Texas and Oklahoma. The firm specializes in supporting non-clinical operations for dental practices, offering a range of centralized services that include human resources, payroll, accounting, bookkeeping, finance, lending, facilities management, and information technology. By providing these essential services, Pearl Street Dental enables partner dentists to focus on delivering comprehensive care in general, specialty, and cosmetic dentistry. The company is committed to enhancing the efficiency and effectiveness of dental practices, ensuring that they are well-equipped with the necessary technology and resources to serve their patients effectively. Pearl Street Dental Management also addresses inquiries through various channels, including online applications, phone calls, and emails.

Renibus Therapeutics is a clinical-stage biotech company transforming outcomes in cardiothoracic surgical patients. It has developed a portfolio of products that activate multiple cytoprotective pathways, including organ protection via preconditioning.

ALX Oncology is a clinical-stage immuno-oncology company based in Burlingame, California, established in 2015. The company specializes in developing innovative therapies aimed at treating various forms of cancer, with a particular focus on its lead product candidate, ALX148. This therapeutic agent is designed to block the CD47 protein, which cancer cells exploit to evade the immune system. ALX148 is currently being investigated for its efficacy in treating myelodysplastic syndromes, acute myeloid leukemia, and several solid tumor types, including head and neck squamous cell carcinoma and certain gastric cancers. The company leverages advanced protein engineering technologies to enhance the affinity of its CD47 blockers, aiming to minimize hematologic toxicities often associated with existing treatments. ALX Oncology's commitment to improving cancer therapies is rooted in pioneering research conducted by its founders at Stanford University.

Verona Pharma plc is a clinical-stage biopharmaceutical company based in London, dedicated to developing and commercializing innovative therapies for respiratory diseases with significant unmet medical needs. Founded in 2005, the company primarily focuses on its lead product candidate, ensifentrine, an inhaled dual inhibitor of phosphodiesterase enzymes 3 and 4, which functions as both a bronchodilator and an anti-inflammatory agent. Ensifentrine is currently in Phase 2b clinical development as a nebulized formulation for the maintenance treatment of chronic obstructive pulmonary disease (COPD), with additional formulations including a dry powder inhaler and a pressurized metered-dose inhaler also under development. In addition to COPD, Verona Pharma is exploring the use of ensifentrine for other respiratory conditions, including cystic fibrosis and asthma, thereby aiming to enhance the health and quality of life for patients suffering from these chronic disorders.

Antheia is a biotechnology company focused on harnessing the medicinal power of nature through innovative manufacturing processes. The company employs synthetic biology to overcome traditional drug manufacturing limitations by reconstructing complex molecules in yeast, eliminating the need for medicinal plants. This approach ensures reliable, consistent, and widespread availability of essential medicines. Antheia's methods transform the pharmaceutical supply chain, offering cost-competitive, plant-based medicines that provide healthcare organizations with natural and healthier medication options.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, focused on developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. Established in 2014, the company utilizes synthetic amplifier technology to enhance the speed and complexity of antibiotic susceptibility testing, thereby significantly improving patient care. By facilitating the rapid selection of personalized antimicrobial therapies, SeLux aims to transform the management of infectious diseases, ultimately saving lives, reducing hospital stays, and combating the growing issue of antibiotic resistance through more targeted treatments.

Silk Road Medical, Inc. is a medical device company based in Sunnyvale, California, that specializes in innovative solutions for treating carotid artery disease. Founded in 2007, the company has developed a unique approach known as transcarotid artery revascularization (TCAR), which aims to reduce the risk of stroke and enhance patient safety during procedures. Silk Road Medical's product portfolio includes the ENROUTE Transcarotid Neuroprotection System, which allows for direct access to the common carotid artery while temporarily reversing blood flow to protect the brain. Additionally, the ENROUTE Transcarotid Stent System and the ENHANCE Transcarotid Peripheral Access Kit support the TCAR procedure by facilitating safe and effective treatment. Through its minimally invasive techniques, Silk Road Medical seeks to establish TCAR as the standard of care for carotid artery disease, demonstrating improved clinical outcomes and reduced complications associated with traditional methods.

Verastem, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative treatments aimed at improving the survival and quality of life for cancer patients. Based in Needham, Massachusetts, Verastem markets COPIKTRA (duvelisib), an oral medication indicated for adult patients with relapsed or refractory chronic lymphocytic leukemia and follicular lymphoma after multiple prior therapies. In addition to this approved therapy, the company is advancing its pipeline with the focal adhesion kinase inhibitor defactinib, which is being studied in combination with immunotherapies for various cancers, including pancreatic and ovarian cancers, as well as non-small cell lung cancer. Verastem's research emphasizes inhibiting critical signaling pathways that promote cancer cell survival and tumor growth, particularly those associated with the RAS/MAPK pathway. The company has formed collaborative agreements with Yakult Honsha Co., Ltd. and CSPC Pharmaceutical Group Limited to enhance its development efforts. Founded in 2010, Verastem continues to focus on late-stage development of its anticancer agents.

Lexicon Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical products to treat various human diseases. The company's portfolio includes several drug candidates in different stages of clinical trials. LX9211 is an orally-delivered small molecule being tested for neuropathic pain treatment. Sotagliflozin, another orally-delivered small molecule, is under investigation for heart failure and type 1 diabetes. Additionally, the company has developed LX4211 for type 2 diabetes, LX2931 for rheumatoid arthritis and other autoimmune diseases, and LX7101 for glaucoma treatment. Lexicon Pharmaceuticals has established collaborations with several pharmaceutical companies, including Bristol-Myers Squibb, Genentech, Organon, Takeda, Symphony Icon, Taconic Farms, and Nuevolution A/S.

Centogene is a prominent genetic biotech company specializing in the diagnosis and analysis of rare inherited diseases. Headquartered in Rostock, Germany, with additional operations in Berlin and Cambridge, Massachusetts, Centogene focuses on transforming clinical, genetic, and biochemical data into actionable medical solutions. The company serves a diverse global patient population and aims to enhance awareness and understanding of rare diseases across various ethnicities. Centogene operates in two main segments: diagnostics, which offers targeted genetic sequencing and diagnostic services, and pharmaceuticals, which collaborates with partners to provide services such as patient recruitment, biomarker discovery, and epidemiological insights. Through its comprehensive approach, Centogene is dedicated to advancing the field of human genetics and improving the lives of patients and their families affected by rare diseases.

Sierra Oncology, Inc. is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing targeted therapies for hematology and oncology patients. Founded in 2003 and headquartered in Vancouver, Canada, the company focuses on delivering innovative treatments for rare forms of cancer. Its lead drug candidate, momelotinib, is a selective inhibitor of JAK1, JAK2, and ACVR1, which has been evaluated in two completed Phase 3 trials for myelofibrosis. In addition, Sierra is advancing SRA737, an inhibitor of Checkpoint kinase 1 currently undergoing Phase 1/2 clinical trials, and SRA141, an inhibitor of cell division cycle 7 kinase in preclinical development. Through its scientific expertise and evidence-based approach, Sierra Oncology aims to transform cancer treatment paradigms and improve patient outcomes.

Choice Health at Home, LLC is a Texas-based provider of home health, hospice, rehabilitation, and personal care services, established in 2007 and headquartered in Tyler. The company specializes in delivering comprehensive care primarily for geriatric patients, offering a range of services that include routine care, nursing, medical consultations, and rehabilitation therapies such as physical, speech, and occupational therapy. Choice Health at Home is committed to providing continuous care that transitions seamlessly from hospital settings to patients' homes, ensuring that individuals receive the support they need throughout their recovery and daily living.

Kezar Life Sciences, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, focused on the discovery and development of small molecule therapeutics aimed at addressing unmet medical needs in autoimmunity and cancer. The company's lead product candidate, KZR-616, is a selective immunoproteasome inhibitor currently undergoing Phase 2 clinical trials for five autoimmune conditions, including lupus nephritis and autoimmune hemolytic anemia, as well as Phase 1b/2 trials in systemic lupus erythematosus. In addition to KZR-616, Kezar is developing KZR-261, which targets oncology and autoimmune indications. Founded in 2015, the company leverages innovative research in protein homeostasis and has established a pipeline of potential therapies to advance treatment options for patients.

Viracta Therapeutics, Inc. is a clinical-stage drug development company based in Cardiff, California, that specializes in precision oncology focused on virus-associated malignancies. The company utilizes a viral activation therapy platform to develop treatments for cancers linked to the Epstein-Barr Virus (EBV) and other virus-related diseases. Its lead investigational drug, nanatinostat, is being evaluated in combination with the antiviral valganciclovir as a potential oral therapy for EBV-positive lymphoma, including post-transplant lymphoproliferative disorder, plasmablastic lymphoma, and angioimmunoblastic T cell lymphoma. Viracta is also exploring the application of this approach to other EBV-associated conditions, such as nasopharyngeal carcinoma and gastric carcinoma. Founded in 2007 and rebranded from HemaQuest Pharmaceuticals in 2015, Viracta Therapeutics is actively conducting multiple clinical trials to advance its therapeutic candidates.

Platelet BioGenesis, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2014. It specializes in the production of donor-independent human platelets derived from pluripotent stem cells for clinical applications. The company has developed a microfluidic bioreactor that enables the generation of functional platelets at commercial scale from human stem cell cultures. These bioreactor-produced platelets are distributed to hospitals and blood banks, providing essential therapeutic resources to patients globally. Through its innovative approach, Platelet BioGenesis is contributing to advancements in biotechnology and the field of transfusion medicine.

4D pharma plc is a research and development company based in Leeds, United Kingdom, specializing in the production of live biotherapeutic products. Founded in 2014, the company focuses on a range of therapeutic areas, including autoimmune diseases, central nervous system disorders, and cancer. Its proprietary MicroRx platform is designed to identify novel bacteria that can provide targeted therapeutic effects, utilizing single strains of bacteria naturally present in the human gut. 4D pharma's product pipeline includes programs for conditions such as irritable bowel syndrome, pediatric Crohn's disease, asthma, and various solid tumors. Currently, the company has two programs in clinical trials and plans to initiate three additional programs in the near future. Notably, 4D pharma has entered into a collaboration with Merck & Co. to evaluate the combination of one of its products with Keytruda for the treatment of solid tumors.

Impel Pharmaceuticals is a late-stage pharmaceutical company dedicated to developing and commercializing innovative therapies for patients facing diseases with significant unmet medical needs, particularly within the central nervous system (CNS). The company leverages its proprietary Precision Olfactory Delivery (POD) system to enhance drug delivery, enabling the administration of therapeutics directly into the upper nasal space. This approach aims to improve treatment efficacy for various conditions by delivering established medications in a more effective manner. Among its key product candidates are TRUDHESA™, designed for the acute treatment of migraines; INP105, which targets agitation and aggression in patients with autism; and INP107, aimed at managing OFF episodes in Parkinson's disease. Impel Pharmaceuticals is committed to advancing its pipeline to address critical health challenges faced by patients.

Kala Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for eye diseases using its proprietary Mucus Penetrating Particles (MPP) technology. This technology enhances drug distribution and pharmacokinetics by coating mucosal surfaces with biocompatible, drug-loaded particles, allowing for improved local drug concentrations while minimizing systemic exposure. Kala's lead product candidate, KPI-121 0.25%, has completed two Phase III clinical trials aimed at providing temporary relief for dry eye disease. Additionally, INVELTYS has also completed two Phase III trials for managing inflammation and pain after ocular surgery. The company is advancing KPI-285, a receptor tyrosine kinase inhibitor, in preclinical studies targeting retinal diseases. Established in 2009 and headquartered in Watertown, Massachusetts, Kala Pharmaceuticals continues to explore diverse product opportunities while focusing on internal development and research collaborations to address significant clinical needs.

Mainstay Medical is a medical device company focused on developing and commercializing ReActiv8, an implantable neurostimulation system designed to treat chronic mechanical low back pain by restoring control to the lumbar stabilizing muscles. Headquartered in Dublin, Ireland, it operates in Ireland, the United States, and Australia and collaborates with scientists and clinical experts to deliver therapies for the large underserved population of people with debilitating chronic low back pain. Founded in 2008, the company aims to provide a restorative treatment that improves function and quality of life by reestablishing muscle control in the lumbar spine.

Immunocore Limited is a biotechnology company based in Abingdon, United Kingdom, with an additional office in Conshohocken. Founded in 1999, the company focuses on the discovery and development of innovative T cell receptor-based therapeutics aimed at addressing significant unmet medical needs in cancer, viral diseases, and autoimmune diseases. Immunocore specializes in engineering T cell receptors (TCRs) and linking them to antibody fragments, which has led to the development of its lead product candidate, IMCgp100, currently undergoing clinical trials for metastatic melanoma. The company's proprietary TCR technology platform is validated and designed for efficient manufacturing, supporting both clinical and commercial supply. Immunocore was previously known as Avidex Limited before adopting its current name in 2008.

Greenbrook TMS Inc. operates a network of outpatient mental health service centers across the United States, specializing in transcranial magnetic stimulation (TMS) therapy. This FDA-cleared, non-invasive treatment offers electromagnetic stimulation to brain regions involved in mood regulation, primarily targeting major depressive disorder and other mental health conditions. Founded in 2011 and headquartered in Toronto, Canada, Greenbrook TMS manages approximately 121 treatment centers nationwide, providing accessible care for individuals seeking innovative solutions for their mental health challenges.

Nature's Fynd is a food company that specializes in producing protein from extremophile organisms discovered in geothermal springs. Founded in 2012 and headquartered in Chicago, Illinois, with an additional office in Bozeman, Montana, the company employs innovative fermentation technology to cultivate its protein. This method significantly reduces the land and water resources typically required for traditional agriculture. Nature's Fynd aims to create foods that not only nourish people but also promote environmental sustainability.

RxSight, Inc. is a medical technology company based in Aliso Viejo, California, focused on enhancing vision for patients after cataract surgery. It has developed the RxSight Light Adjustable Lens system, which includes the Light Adjustable Lens (LAL), a Light Delivery Device (LDD), and associated accessories. This innovative technology is the first of its kind to allow healthcare professionals to customize and optimize visual acuity post-surgery, enabling precise reshaping of the lens to meet individual patient needs. Additionally, the LAL features ActivShield technology, providing built-in UV protection. Established in 1997 and originally named Calhoun Vision, Inc., the company rebranded to RxSight, Inc. in 2017.

Scholar Rock, Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the discovery and development of biologic therapies that selectively target dysregulated growth factors within disease microenvironments. The company's innovative approach focuses on modulating supracellular activation to address serious diseases, including fibrosis, musculoskeletal disorders, immuno-oncology, and autoimmune diseases. Scholar Rock's lead product candidate, SRK-015, is a first-in-class inhibitor designed to target the activation of the growth factor myostatin in skeletal muscle, specifically for the treatment of spinal muscular atrophy. The company is advancing this candidate through clinical development while also leveraging its proprietary platform to create a pipeline of additional product candidates aimed at transforming treatment for various serious conditions, including other neuromuscular disorders, cancer, and anemia.

SpendMend is a healthcare organization that focuses on helping healthcare entities identify and mitigate financial leakage. The company provides spend visibility and audit recovery services aimed at detecting payment errors and contract non-compliance within clients' operating expenses. By utilizing a technology-driven platform, SpendMend enables healthcare organizations to generate cost savings and enhance their cost cycle management. This approach not only helps clients shrink financial losses but also prevents future occurrences, effectively addressing control gaps that can lead to over-payments.

ReMed provides rehabilitation services, neurobehavioral services, and supported living for people with mild, moderate, and severe brain injuries. They offer residential, outpatient, and home and community-based treatment.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focusing on the development of therapies for immune-mediated diseases. Established in 2010, the company specializes in creating immunotherapies utilizing human microbiome-derived bacteria. Its innovative platform includes a collection of defined bacterial consortia, proprietary assays for selecting effective strains, and extensive datasets from human interventional studies. Vedanta Biosciences also possesses capabilities for cGMP-compliant manufacturing, allowing for the production of live bacterial therapies in powder form. This enables healthcare providers to administer oral treatments aimed at addressing autoimmune and inflammatory diseases efficiently, potentially pioneering a new category of therapies based on the human microbiome.

Enable Injections designs and manufactures wearable devices that deliver injectable drugs directly into the subcutaneous tissue. The system accepts standard vials, syringes, or cartridges, automatically reconstitutes lyophilized solutions, warms the drug, and injects high‑viscosity or high‑volume payloads up to 20 ml. Users place the device on the skin, press a central button, and monitor delivery progress through a viewing window before disposing of the single‑use injector. The company also offers transfer systems for partial or multi‑vial filling and a Bluetooth‑enabled version that can connect to smartphones. Founded in 2010, the company is headquartered in Cincinnati, Ohio, and targets a growing market for self‑administration of biologics and other therapeutics.

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary platform utilizes advances in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Selecta's lead product, SEL-212, has successfully completed Phase II clinical trials for chronic refractory gout. Additionally, the company is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences has established collaborations with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development capabilities.

Epic Healthcare Staffing is a diversified national provider of staffing services to the healthcare and bio‑pharmaceutical industries.

Syros Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently in Phase II clinical trials for specific patient populations with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor under investigation in a Phase I clinical trial for advanced solid tumors. Syros is also engaged in collaborative research, including a partnership with Incyte Corporation aimed at identifying therapeutic targets for myeloproliferative neoplasms and a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. With a focus on mapping gene regulatory circuits, Syros leverages its proprietary platform and expertise to address significant unmet medical needs in oncology. Founded in 2011, the company aims to establish new standards of care for patients with hematologic malignancies.

GenapSys, Inc. develops innovative DNA sequencing technologies aimed at enhancing applied genomic testing and medical sequencing. Its primary product, the GenapSys Sequencer, utilizes a proprietary electrical-based detection method for single nucleotide incorporations, making it suitable for a wide range of applications, including research, gene editing, drug development, agriculture, forensics, and food testing. The sequencer is designed for versatility, allowing it to operate in various lab environments and automate clonal amplification. GenapSys is also focused on collaborating with local health agencies and researchers to facilitate rapid sequencing capabilities that can aid in controlling outbreaks. Its compact design enables deployment in diverse locations, such as hospitals and public transport hubs, for efficient virus sample analysis. Founded in 2010 and headquartered in Redwood City, California, GenapSys is committed to providing accessible and precise genetic testing solutions.

DermCare Management is a dermatology practice management company founded by experienced dermatology professionals. It focuses on partnering with dermatologists to enhance patient loyalty and practice growth by combining clinical expertise with management support. The company provides administrative assistance and resources, allowing dermatologists to concentrate on delivering high-quality care. DermCare Management aims to foster a team-oriented environment in healthcare, emphasizing collaboration and effective management to ensure the continued success of its partner practices. Through its services, DermCare Management addresses the unique challenges faced by dermatology practices, enabling them to thrive in a competitive landscape while maintaining a commitment to exceptional patient care.

Equillium is a clinical-stage biotechnology company focused on developing novel therapeutics for autoimmune and immuno-inflammatory disorders with high unmet medical need. Its lead candidate, EQ001 (Itolizumab), is a first-in-class monoclonal antibody that selectively targets the CD6 immune receptor to downregulate pathogenic effector T cells while preserving regulatory T cells by modulating the CD6-ALCAM signaling pathway. The approach targets a range of immuno-inflammatory diseases, including graft-versus-host disease, asthma, uveitis, colitis, lupus, and multiple sclerosis. Equillium aims to advance its programs through clinical development and may commercialize products independently or through partnerships or strategic transactions to monetize its pipeline.

LogicBio Therapeutics, Inc. is a genome editing company dedicated to developing innovative treatments for rare diseases, particularly for pediatric patients with significant unmet medical needs. Utilizing its proprietary GeneRide technology platform, LogicBio aims to integrate corrective genes into patients' genomes to achieve therapeutic effects. The company's lead product candidate, LB-001, targets Methylmalonic Acidemia, a serious condition that manifests at birth. Additionally, LogicBio is advancing other product candidates, including LB-101 and LB-301, the latter developed in collaboration with Takeda Pharmaceutical Company to address Crigler-Najjar syndrome. The company also partners with the Children's Medical Research Institute to create new viral vectors, enhancing the potential of its gene therapy approaches. Founded in 2014, LogicBio is headquartered in Lexington, Massachusetts.

Xeris Biopharma Holdings is a specialty pharmaceutical company focused on developing and commercializing innovative therapies for patients in endocrinology, neurology, and gastroenterology. The company utilizes its proprietary formulation technologies, XeriSol and XeriJect, to create ready-to-use, liquid-stable injectables that facilitate subcutaneous and intramuscular delivery of various therapeutic agents. Xeris offers three commercially available products: Gvoke, a liquid glucagon for severe hypoglycemia; Keveyis, the first FDA-approved treatment for primary periodic paralysis; and Recorlev, approved for endogenous hypercortisolemia in adults with Cushing's Syndrome. Xeris Biopharma's formulation platforms aim to improve patient and caregiver ease of use by eliminating reconstitution, ensuring long-term stability at room temperature, and reducing injection volume, thereby enhancing healthcare delivery and potentially lowering costs for the healthcare system. The company is also advancing a pipeline of development programs to expand its product offerings.

Codex DNA is a biology company helping researchers with the tools they need to securely design, code, and create synthetic DNA. The company is on a mission to help scientific researchers in both academic and commercial settings with the hardware, software, materials, and methodologies required to rapidly and accurately write large quantities of synthetic genes. To, in effect, build biology. Its gene synthesis portfolio reduces the turnaround time for synthesizing workflows from weeks and months to days and hours and includes the BioXp system, DNA services, Gibson Assembly reagents, and Vmax chemically competent cells. In addition to automating, speeding, and optimizing DNA design and synthesis, Codex DNA and the BioXp system ensure your designs stay in your hands, marrying speed and security for innovators in drug discovery, vaccine development, precision medicine, and beyond. Co-founded by Dan Gibson — the creator of the industry-standard Gibson Assembly methodology — Codex DNA is attempting nothing less than changing everything.

MolecuLight specializes in innovative imaging solutions for wound care, focusing on the detection of harmful bacteria and accurate wound measurement. The company develops portable handheld optical imaging devices that allow medical practitioners to visualize bacteria and assess wound status directly at the point of care. These devices facilitate the analysis and visual detection of bacteria, provide procedural guidance, and enable the assessment of viable and nonviable tissue. By offering these capabilities, MolecuLight supports healthcare professionals in selecting appropriate therapies for their patients and effectively monitoring wound healing progress.

ObsEva SA is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, dedicated to developing innovative therapeutics for women's reproductive health and pregnancy. Founded in 2012 by Ernest Loumaye and André Chollet, the company focuses on addressing serious conditions affecting women. Its key products in development include Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist aimed at treating pain from endometriosis and heavy menstrual bleeding associated with uterine fibroids. ObsEva is also working on OBE022, a once-daily oral prostaglandin F2α receptor antagonist designed for managing preterm labor between 24 and 34 weeks of gestation, and Nolasiban, an oral oxytocin receptor antagonist intended to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company operates primarily within the Swiss market while targeting global solutions for women's reproductive health needs.

Talphera is a specialty pharmaceutical company dedicated to developing and commercializing therapies tailored for medically supervised environments. The company offers innovative products such as NanoTab, designed for oral transmucosal administration, and the Sufentanil NanoTab PCA system, which is a sublingual patient-controlled analgesia system aimed at managing acute postoperative pain in hospital settings. Additionally, Talphera provides Sufentanil NanoTab BTP management systems for cancer pain treatment and Sufentanil/Triazolam NanoTab, which delivers both analgesia and sedation for minor outpatient procedures. The company's diverse portfolio also includes nafamostat product candidates and pre-filled syringe product candidates, reflecting its commitment to addressing critical pain management needs.

RefleXion Medical Inc. is a medical equipment company based in Hayward, California, focused on revolutionizing cancer treatment through its biologically-guided radiotherapy system (BgRT). This innovative technology allows tumors to continuously signal their location during treatment, enabling the simultaneous targeting of multiple tumors, even in cases of metastasized cancer. The RefleXion X1 machine is cleared for various forms of radiotherapy, including stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT system utilizes positron-emission tomography (PET) imaging data to synchronize tumor location information with the linear accelerator, allowing for real-time adjustments in treatment delivery with subsecond latency. RefleXion Medical has established strategic collaborations with Telix Pharmaceuticals Limited and HealthMyne Inc. since its incorporation in 2009.

Summit Healthcare REIT, based in Laguna Hills, California, operates as a real estate investment trust (REIT) focusing on the acquisition and ownership of assisted living, memory care, and skilled nursing facilities. Its portfolio spans various geographic regions and is diversified across top-tier operators in the senior housing sector.

Evolus, Inc. is a performance beauty company headquartered in Newport Beach, California, focused on the medical aesthetics market. Established in 2012, the company specializes in providing innovative products that cater to the needs of physicians and their patients. Its flagship product, Jeuveau, is a proprietary formulation of a 900 kilodalton purified botulinum toxin type A, designed for the temporary improvement of moderate to severe glabellar lines, commonly referred to as frown lines. Evolus targets the self-pay aesthetic market, where patients pay directly for treatments, distinguishing itself by offering a compelling value proposition to both physicians and consumers. The company aims to deliver breakthrough products that enhance aesthetic procedures and expand choices within this growing market.

Continuing Healthcare Solutions is a provider of long-term care and healthcare services dedicated to delivering exceptional care to its residents while upholding dignity and respect. The company offers a comprehensive range of services, including assisted living, skilled nursing care, rehabilitation services, memory care, behavioral health, respiratory care, wound management, and hospice care. By focusing on compassionate care and maintaining a strong reputation as a preferred healthcare provider, Continuing Healthcare Solutions emphasizes the importance of hiring, training, and retaining quality healthcare professionals. This commitment positions the company as a leader in the communities it serves.

AliveCor, Inc. specializes in developing digital medical-grade electrocardiograms, enabling users to monitor their heart health through mobile technology. The company's flagship product, KardiaMobile, is a personal mobile EKG device that provides instant detection of common heart arrhythmias, along with features for blood pressure and weight tracking, as well as storage for recorded EKGs. Additionally, AliveCor offers KardiaMobile 6L, a six-lead EKG device that allows patients to share detailed EKG readings with healthcare providers. The company also operates KardiaCare, a digital health subscription service that empowers users to manage their heart health conveniently at home. Founded in 2010 and incorporated in 2011, AliveCor is headquartered in Mountain View, California, and is recognized for its innovative contributions to cardiac care through the integration of machine learning techniques.

Karius, Inc. is a life sciences company based in Redwood City, California, with an additional office in Menlo Park. Founded in 2014, Karius specializes in generating genomic insights for infectious diseases through its innovative Karius Test. This non-invasive blood test utilizes sequencing of microbial cell-free DNA to identify and quantify a wide range of pathogens, including bacteria, DNA viruses, fungi, and parasites. The Karius Test is particularly useful in the diagnosis of complicated pneumonia, infections in immunocompromised patients, and endocarditis, enabling clinicians to make rapid and informed treatment decisions. Karius operates a CLIA-certified and CAP-accredited laboratory, providing high-complexity clinical laboratory testing and offering services for pathogen biomarker detection aimed at biopharmaceutical companies. The company is dedicated to advancing the understanding and management of infectious diseases, striving for a future where these conditions pose less of a threat to human health.

Nevakar Inc. is a pharmaceutical company established in 2015 and headquartered in Bridgewater, New Jersey. It specializes in the development of innovative ophthalmic and injectable products, aiming to enhance existing FDA-approved molecules to meet unmet clinical and commercial needs. The company emphasizes intensive research and development, supported by a state-of-the-art infrastructure located in the New Jersey Center of Excellence. With a management and leadership team boasting significant industry experience, Nevakar is committed to advancing its portfolio through rigorous clinical efforts and innovative solutions.

QuVa Pharma, Inc. is a 503B outsourcing company that specializes in the manufacturing and supply of compounded sterile preparations. Founded in 2015 and headquartered in Sugar Land, Texas, with additional manufacturing facilities in Temple, Texas, and Bloomsbury, New Jersey, QuVa Pharma produces a range of specialty admixtures in IV bags, syringes, and specialized vials. The company focuses on delivering vital compounded medications for various therapeutic areas, including obstetrics, anesthesia, general medicine, cardiovascular care, and pain management. By serving compliance-oriented healthcare facilities across the United States, QuVa Pharma plays a crucial role in providing ready-to-use pharmaceutical products, including antibiotics, electrolytes, and anesthetics, to hospitals and long-term care facilities.

Cardiac Dimensions, Inc. is a medical device company focused on developing innovative minimally invasive treatments for heart failure and associated cardiovascular issues. Founded in 2000 and headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany, the company is known for its Carillon Mitral Contour System. This permanent implant is designed specifically for the treatment of functional mitral regurgitation, utilizing a catheter-based approach to reshape the mitral valve and effectively reduce regurgitation. By providing a non-surgical option for patients, Cardiac Dimensions aims to improve outcomes for those suffering from heart-related conditions.

Xeris Biopharma Holdings is a specialty pharmaceutical company focused on developing and commercializing innovative therapies for patients in endocrinology, neurology, and gastroenterology. The company utilizes its proprietary formulation technologies, XeriSol and XeriJect, to create ready-to-use, liquid-stable injectables that facilitate subcutaneous and intramuscular delivery of various therapeutic agents. Xeris offers three commercially available products: Gvoke, a liquid glucagon for severe hypoglycemia; Keveyis, the first FDA-approved treatment for primary periodic paralysis; and Recorlev, approved for endogenous hypercortisolemia in adults with Cushing's Syndrome. Xeris Biopharma's formulation platforms aim to improve patient and caregiver ease of use by eliminating reconstitution, ensuring long-term stability at room temperature, and reducing injection volume, thereby enhancing healthcare delivery and potentially lowering costs for the healthcare system. The company is also advancing a pipeline of development programs to expand its product offerings.

VitalConnect is a company that specializes in wearable biosensor technology for wireless patient monitoring. It develops innovative solutions that enable continuous monitoring and recording of patients' vital signs through an adhesive patch applied to the body. The technology integrates expertise in biomedical engineering, data analytics, and chip design, allowing vital data to be displayed on mobile devices and computer systems. This capability empowers healthcare professionals to respond promptly to urgent situations and gain valuable insights into patient health, facilitating informed decision-making in both inpatient and outpatient settings, including hospital monitoring, post-discharge care, and cardiac monitoring.

Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative products aimed at improving cancer care. Founded in 2010 and headquartered in Los Angeles, California, the company primarily focuses on the treatment of various forms of cancer, particularly through its lead product, NERLYNX, an oral formulation of neratinib designed for HER2-positive breast cancer patients. Additionally, Puma is developing PB357, an irreversible tyrosine kinase inhibitor that targets the epidermal growth factor receptors HER1, HER2, and HER4. The company operates under a licensing agreement with Pfizer for the development and commercialization of its drug candidates, including oral and intravenous forms of neratinib, as well as PB357. With a commitment to enhancing treatment outcomes, Puma Biotechnology is focused on advancing its clinical programs and bringing effective therapies to market for cancer patients.

AirXpanders, Inc. was a medical device company headquartered in San Jose, California, specializing in the design, manufacture, sale, and distribution of innovative medical devices aimed at improving breast reconstruction outcomes. Founded in 2005, the company developed the AeroForm Tissue Expander System, a needle-free and patient-controlled device specifically designed for use in two-stage breast reconstruction following mastectomy. This system allowed patients to expand tissue in a controlled manner before the insertion of breast implants. Despite its advancements in medical technology, AirXpanders filed for Chapter 7 bankruptcy and ceased operations on September 25, 2019.

Castle Biosciences is a molecular diagnostics company headquartered in Friendswood, Texas, that develops and commercializes gene‑expression‑profile tests for dermatologic cancers, uveal melanoma, and Barrett’s esophagus. Its flagship product, DecisionDx‑Melanoma, predicts the risk of metastasis in stage I and II cutaneous melanoma by analyzing 31 tumor‑derived genes. The company also offers DecisionDx‑UM for uveal melanoma, DecisionDx‑SCC for cutaneous squamous cell carcinoma, MyPath Melanoma for diagnostically challenging melanocytic lesions, and TissueCypher for predicting progression of high‑grade dysplasia in Barrett’s esophagus. Tests are delivered to physicians, physician assistants, and nurse practitioners to support personalized treatment decisions. Founded in 2007, Castle Biosciences focuses on providing clinically actionable genomic information to improve cancer diagnosis and management.

Cerapedics, Inc. is an orthobiologics company specializing in the development and commercialization of innovative synthetic small peptide technologies for bone healing. Founded in 2000 and headquartered in Westminster, Colorado, with an additional office in Denver, the company offers products such as i-FACTOR, a peptide-enhanced bone graft designed to stimulate the natural healing process in orthopedic applications, and i-FACTOR+ MATRIX for surgical implantation. Cerapedics focuses on creating biomimetic solutions, specifically its proprietary small peptide molecule (P-15), aimed at improving outcomes in spinal fusion surgery and other orthopedic procedures. The company's technology strives to provide safer and more predictable bone formation compared to traditional bone growth factors.

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Plano, Texas, that specializes in developing novel therapeutics for serious and life-threatening diseases. The company targets molecular pathways involved in cellular metabolism and inflammation, with a focus on conditions such as chronic kidney disease (CKD), pulmonary arterial hypertension, and neurodegenerative diseases. Reata's pipeline includes bardoxolone methyl, which is undergoing Phase III trials for CKD caused by Alport syndrome and for pulmonary arterial hypertension associated with connective tissue disease. Additionally, omaveloxolone is in Phase II trials for Friedreich’s ataxia. The company is also exploring RTA 901 for neurological conditions and has RORgT inhibitors in preclinical development for autoimmune and inflammatory diseases. Reata has established strategic collaborations for the development and commercialization of its therapies in various Asian markets and with AbbVie for certain Nrf2 activators. Founded in 2002 and rebranded in 2005, Reata Pharmaceuticals is committed to advancing innovative treatments for complex medical challenges.

Oxford Biotherapeutics Ltd is a biotechnology company focused on developing innovative antibody therapies for cancer treatment. The company specializes in antibody-drug conjugates, aiming to create targeted therapies that improve treatment outcomes for patients. Its proprietary OGAP (Oxford Genome Anatomy Project) platform, one of the largest human protein databases globally, facilitates the identification of validated and novel antigen targets across various cancer types. Key products include OBT076, an antibody-drug conjugate aimed at treating high-risk HER2 negative breast cancer and other solid tumors. Additionally, Oxford Biotherapeutics is developing antibody-based treatments for conditions such as acute myeloid leukemia and plans to integrate companion diagnostics into its programs to enhance disease management. Established in 2003, the company is based in Oxon, United Kingdom, with an operational site in San Jose, California, and maintains strategic collaborations with leading antibody-focused firms to broaden its therapeutic pipeline.

ConforMIS is a United States-based medical technology company that specializes in developing, manufacturing, and selling joint replacement implants and instruments tailored to each patient's unique anatomy. Utilizing its proprietary iFit Image-to-Implant technology platform, ConforMIS creates personalized knee and hip implants, as well as single-use surgical instruments. The company's offerings include various partial and total knee replacement implants, such as the iTotal CR, iTotal PS, iDuo, and iUni. These products are delivered directly to hospitals and ambulatory surgical centers, ensuring that each implant is individually sized and shaped for optimal fit.

Eiger BioPharmaceuticals is a late-stage biopharmaceutical company headquartered in Palo Alto, California, specializing in the development of targeted therapies for rare and ultra-rare diseases. The company's lead product candidate, Lonafarnib, is an orally bioavailable small molecule currently in Phase 3 clinical trials for the treatment of hepatitis delta virus (HDV) infection, a life-threatening condition with significant unmet medical needs. Eiger's pipeline also includes Lambda, which is being evaluated in Phase 2 trials for HDV treatment, and Lonafarnib is being explored for its potential use in treating progeria and progeroid laminopathies. Additionally, Avexitide, which has completed Phase 2 trials for post-bariatric hypoglycemia, is also undergoing clinical evaluation for congenital hyperinsulinism. Eiger's strategic focus is on efficient drug development to deliver safe and effective therapies to patients suffering from these serious conditions.

Strongbridge Biopharma plc is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for rare diseases with significant unmet medical needs. The company’s primary focus is on rare endocrine disorders, exemplified by its product candidates, Recorlev, a cortisol synthesis inhibitor currently in Phase III trials for endogenous Cushing's syndrome, and Veldoreotide, a somatostatin analog that has completed Phase II trials for acromegaly. Strongbridge also offers Keveyis, an oral carbonic anhydrase inhibitor approved for treating specific forms of periodic paralysis in the United States. Founded in 1996 and headquartered in Trevose, Pennsylvania, the company aims to leverage a concentrated prescriber base for its products and plans to utilize a targeted sales force for marketing in the U.S., European Union, and other key markets. Additionally, Strongbridge seeks to enhance its portfolio through the in-licensing or acquisition of complementary products that align with its focus on rare endocrine conditions.

Veran Medical Technologies, Inc. is a medical device company specializing in minimally invasive therapeutic devices for interventional oncology. Headquartered in St. Louis, Missouri, the company focuses on developing products that assist physicians in diagnosing diseases and delivering targeted therapies. Its offerings include the SPiNView thoracic navigation system, an electromagnetic device designed for the biopsy of solitary pulmonary nodules, and the ig4 IR System, which aids in performing biopsies and other procedures for the lungs, liver, and kidneys. Additionally, Veran Medical provides various instruments such as the vPad2 tracker device and the SPiNPerc hybrid diagnostic tool. The company's innovative solutions utilize advanced imaging technologies to create dynamic 3D maps of respiratory pathways, enhancing procedural planning and navigation, ultimately helping clinicians to expedite cancer diagnosis and treatment. Founded in 2003, Veran Medical Technologies is committed to improving patient outcomes through precision-guided interventions.

Bi02 Medical, Inc. is a medical device company that specializes in designing, developing, manufacturing, and commercializing innovative solutions for clinical needs. The company's flagship product, the Angel Catheter, is an inferior vena cava (IVC) filter aimed at preventing pulmonary embolism and enabling access to the central venous system in critically ill patients. This catheter-based device allows for the administration of medications, fluids, or blood products, as well as blood sampling and monitoring of central venous pressure. Bi02 Medical operates through a network of distribution partners globally. Founded in 2006, the company is headquartered in San Antonio, Texas, and maintains a research and development and manufacturing facility in Golden, Colorado.

CVRx, Inc. is a medical device company headquartered in Minneapolis, Minnesota, that specializes in the development of implantable technologies for the treatment of high blood pressure and heart failure. Founded in 2000, the company has created Barostim NEO, a neuro-modulation therapy that activates the body's natural mechanisms to regulate blood pressure and address heart failure progression. This therapy utilizes an implantable system that is tailored to the individual needs of patients. CVRx also offers the Rheos platform, which includes an implantable pulse generator and carotid sinus leads designed to deliver therapeutic energy to the carotid arteries. With a focus on minimally invasive solutions, CVRx primarily serves patients and healthcare professionals in the United States and internationally, including markets in the United Kingdom, the Netherlands, Italy, and Germany.

Senseonics Holdings, Inc. is a medical technology company based in Germantown, Maryland, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems for individuals with diabetes. Founded in 1996, the company focuses on innovative and long-term implantable glucose monitoring solutions that utilize advanced fluorescence sensing technology. Its flagship products, Eversense and Eversense XL, are implantable CGM systems designed to monitor glucose levels for up to 90 and 180 days, respectively. These products aim to provide users with a reliable and stable means of glucose management, enhancing their ability to live confidently and manage their diabetes effectively. The majority of Senseonics' revenue comes from international markets, reflecting its strong presence in Europe.

Ignyta, Inc. is a biotechnology company focused on discovering, developing, and commercializing molecularly targeted therapies aimed at treating cancer and autoimmune diseases. Established in 2011 and based in San Diego, California, Ignyta is dedicated to advancing personalized medicine by integrating therapeutic approaches with companion diagnostics. Its notable products include entrectinib, a tyrosine kinase inhibitor targeting various receptor proteins, and RXDX-105, which is designed for RET-driven solid tumors. The company seeks to improve treatment outcomes by identifying patients most likely to benefit from specific therapies through biomarker-based diagnostics. In 2018, Ignyta became a subsidiary of Roche Holdings, further enhancing its capabilities in precision medicine.

Monteris Medical, Inc. is a medical device company specializing in the development and marketing of innovative technologies for the treatment of brain diseases. Founded in 1999 and based in Plymouth, Minnesota, with additional offices in Minneapolis and Winnipeg, the company focuses on minimally-invasive, MRI-guided, and robotically controlled neurosurgical procedures. Its flagship product, the NeuroBlate System, utilizes focused laser energy to safely ablate pathological brain lesions, such as tumors, while minimizing damage to surrounding healthy tissue. Monteris Medical also provides various stereotactic anchoring devices and stabilization systems for enhanced precision during image-guided procedures. The company markets its products directly to neurosurgeons in the United States, aiming to improve surgical outcomes through advanced technology.

Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of microRNA-targeted therapies for various diseases. Founded in 2007 and headquartered in San Diego, California, the company focuses on innovative treatments for conditions such as kidney diseases and viral infections. Its lead product candidates include RG-012, an anti-miR targeting miR-21, currently in Phase II clinical trials for Alport syndrome, and RGLS4326, an anti-miR targeting miR-17, which is undergoing Phase Ib clinical trials for autosomal dominant polycystic kidney disease. Additionally, Regulus is advancing a pipeline of preclinical drug candidates, including RGLS5579 to inhibit miR-10b, as well as programs aimed at treating Hepatitis B virus and Non-Alcoholic Steatohepatitis. The company's work leverages the recent scientific advancements in microRNA research, which play a crucial role in regulating gene expression.

Omeros Corporation is a Seattle-based biopharmaceutical company that focuses on discovering, developing, and commercializing small-molecule and protein therapeutics targeting inflammation, complement-mediated diseases, and disorders of the central nervous system. The company offers OMIDRIA, a product used during cataract surgery in the United States. Omeros is advancing several clinical programs, including narsoplimab, which is in Phase III trials for conditions such as hematopoietic stem-cell transplant-associated thrombotic microangiopathy and immunoglobulin A nephropathy, as well as Phase II trials for lupus nephritis. Other key programs include OMS405, targeting opioid and nicotine addiction, and OMS527, aimed at treating addiction and movement disorders. The company's preclinical pipeline includes compounds addressing various conditions, such as paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders. Founded in 1994, Omeros is dedicated to addressing both large-market and orphan indications through innovative therapeutic approaches.

ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing specialty plasma-derived biologics aimed at treating immune deficiencies and infectious diseases in the United States. The company offers a range of products, including BIVIGAM and ASCENIV, both intravenous immune globulin therapies for primary humoral immunodeficiency, as well as Nabi-HB, which is used for acute exposure to Hepatitis B. ADMA is also involved in the development of additional plasma-derived therapeutics, particularly targeting infections like S. pneumonia. To support its operations, the company runs FDA-licensed source plasma collection facilities known as ADMA BioCenters, which contribute to the supply of plasma necessary for its product manufacturing. ADMA Biologics distributes its products through independent distributors, sales agents, specialty pharmacies, and other healthcare providers. Founded in 2004 and based in Ramsey, New Jersey, ADMA is dedicated to serving niche patient populations, particularly those with compromised immune systems.

Nuvectra Medical is a neurostimulation medical device company dedicated to developing and commercializing its technology platform aimed at treating various disorders through the stimulation of nervous system tissues. The company specializes in manufacturing medical devices designed for chronic neurological conditions. Its flagship product, the Algovita Spinal Cord Stimulation (SCS) System, is approved for the management of chronic pain affecting the trunk and limbs. Nuvectra primarily operates within the United States and focuses on enhancing the quality of life for patients suffering from chronic pain through innovative neurostimulation solutions.

Superior Biologics is a prominent provider of intravenous and injectable medications tailored for patients with chronic disorders. Headquartered in Hawthorne, New York, the company primarily serves the tri-state area of New York, New Jersey, and Connecticut, while also being licensed to provide services in various other states. Superior Biologics is committed to delivering cost-effective, patient-specific services that empower individuals to maintain normal lives and achieve optimal therapeutic outcomes. The company prioritizes understanding the evolving needs of patients and their families, offering personalized support backed by a team of highly qualified professionals.

Bi02 Medical, Inc. is a medical device company that specializes in designing, developing, manufacturing, and commercializing innovative solutions for clinical needs. The company's flagship product, the Angel Catheter, is an inferior vena cava (IVC) filter aimed at preventing pulmonary embolism and enabling access to the central venous system in critically ill patients. This catheter-based device allows for the administration of medications, fluids, or blood products, as well as blood sampling and monitoring of central venous pressure. Bi02 Medical operates through a network of distribution partners globally. Founded in 2006, the company is headquartered in San Antonio, Texas, and maintains a research and development and manufacturing facility in Golden, Colorado.

Omeros Corporation is a Seattle-based biopharmaceutical company that focuses on discovering, developing, and commercializing small-molecule and protein therapeutics targeting inflammation, complement-mediated diseases, and disorders of the central nervous system. The company offers OMIDRIA, a product used during cataract surgery in the United States. Omeros is advancing several clinical programs, including narsoplimab, which is in Phase III trials for conditions such as hematopoietic stem-cell transplant-associated thrombotic microangiopathy and immunoglobulin A nephropathy, as well as Phase II trials for lupus nephritis. Other key programs include OMS405, targeting opioid and nicotine addiction, and OMS527, aimed at treating addiction and movement disorders. The company's preclinical pipeline includes compounds addressing various conditions, such as paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders. Founded in 1994, Omeros is dedicated to addressing both large-market and orphan indications through innovative therapeutic approaches.

Aratana Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutics for dogs and cats in the United States. Founded in 2010 and headquartered in Leawood, Kansas, the company focuses on addressing unmet medical needs in companion animal care through high-quality medicines. Its product portfolio includes various therapeutics, such as NOCITA for post-operative pain management in dogs, ENTYCE for appetite stimulation, and GALLIPRANT for pain and inflammation associated with osteoarthritis. Aratana is also advancing treatments for conditions like osteosarcoma in dogs and a range of therapies for cats, including a specialized formulation for pain management and treatments for feline herpes virus-induced conditions. The company has established collaboration agreements with other health organizations to enhance the development and commercialization of its products.

MDRejuvena is dedicated to and passionate about providing products that rejuvenate, enhance, and maintain skin health for the patients of physicians and skincare professionals worldwide. It specializes in the fields of fitness, healthcare, and wellness. It was founded in 2015 and headquartered in San Diego, California.

Zyga Technology, Inc. is a medical device company focused on the research, design, development, and commercialization of minimally invasive products aimed at addressing underserved conditions of the lumbar spine. Founded in 2008 and headquartered in Minnetonka, Minnesota, the company offers the SImmetry Sacroiliac Joint Fusion System, which provides a surgical solution for sacroiliac joint fusion in patients with conditions such as sacroiliac joint disruptions and degenerative sacroiliitis. Additionally, Zyga is developing the Glyder Facet Restoration System, an investigational device intended to treat chronic facetogenic pain. The company is supported by a team of experienced engineers, marketing personnel, and management dedicated to advancing medical devices in the spine industry. Zyga Technology operates as a subsidiary of RTI Surgical, Inc.

Continuum Health Alliance, LLC ("Continuum") is a regional healthcare management company founded in 1998 by nationally-renowned pediatrician John M. Tedeschi, MD. Continuum offers operational oversight and optimizes business processes, enabling physician groups and hospitals to better serve their patients. The Company's comprehensive service portfolio is built on five pillars. Continuum offers administrative solutions, financial services, revenue cycle management, information technology, and population management services, which addresses new governmental guidelines and healthcare initiatives. Continuum also collaborates with hospitals to create and manage medical group networks, hospitalist programs, and innovative hospital-based programs; and helps medical providers navigate and respond to the regulatory requirements mandated by America's health care reform legislation. The Company presently oversees an aggregate client workforce of more than 4,000 employees located in approximately 200 medical offices and hospital settings

Venus Concept Inc. is a medical aesthetic technology company based in Toronto, Canada, specializing in the development and commercialization of minimally invasive and non-invasive devices and treatments. Its diverse product portfolio includes platforms such as Venus Versa, a multi-treatment solution for aesthetic procedures; Venus Legacy, designed for complex face and body needs; and Venus Viva, a customizable skin resurfacing device. The company also offers solutions for hair restoration, including NeoGraft and ARTAS robotic systems, which facilitate follicle harvesting and implantation. Other products address skin tightening, fat reduction, and vaginal health restoration. Venus Concept is recognized for its innovative approach and commitment to enhancing patient experiences within the medical aesthetics sector, generating a significant portion of its revenue from the United States.

Ocera Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative treatments for patients suffering from acute and chronic liver diseases. The company's primary focus is on its lead product, OCR-002, an ammonia scavenger designed to address hyperammonemia through both intravenous and oral formulations. Recently, Ocera completed a Phase 2b clinical trial, known as STOP-HE, which assessed the safety and efficacy of OCR-002 in alleviating neurocognitive symptoms associated with acute hepatic encephalopathy in hospitalized patients with elevated ammonia levels. Ocera is currently preparing for a meeting with the FDA to discuss the intravenous program and potential future development pathways for its therapeutics.

AlterG, Inc. is a manufacturer and distributor of rehabilitation and therapy equipment, headquartered in Fremont, California. The company specializes in developing innovative devices, most notably the Anti-Gravity Treadmill, which utilizes pressure-unweighting technology to facilitate physical therapy for individuals recovering from lower extremity injuries or surgeries. AlterG also offers the Stride Smart Gait Analytics treadmill, designed to enhance the benefits of anti-gravity therapy, and the AlterG Digital Video Monitoring System, which fosters collaboration between patients and therapists to optimize rehabilitation outcomes. Additionally, the company provides various accessories such as standard and performance shorts, as well as mats, to complement its rehabilitation equipment. Founded in 2004, AlterG aims to empower individuals to achieve their physical goals by improving mobility, reducing pain, and accelerating recovery times.

Pharming Group is a global biopharmaceutical company focused on developing innovative protein replacement therapies and precision medicines aimed at treating rare, debilitating, and life-threatening diseases. The company is dedicated to addressing the needs of underserved patients by commercializing and advancing an extensive portfolio of therapeutic products, including Ruconest. With a primary revenue stream derived from the United States, Pharming Group aims to transform the lives of individuals affected by these rare conditions through its specialized treatments.

ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing specialty plasma-derived biologics aimed at treating immune deficiencies and infectious diseases in the United States. The company offers a range of products, including BIVIGAM and ASCENIV, both intravenous immune globulin therapies for primary humoral immunodeficiency, as well as Nabi-HB, which is used for acute exposure to Hepatitis B. ADMA is also involved in the development of additional plasma-derived therapeutics, particularly targeting infections like S. pneumonia. To support its operations, the company runs FDA-licensed source plasma collection facilities known as ADMA BioCenters, which contribute to the supply of plasma necessary for its product manufacturing. ADMA Biologics distributes its products through independent distributors, sales agents, specialty pharmacies, and other healthcare providers. Founded in 2004 and based in Ramsey, New Jersey, ADMA is dedicated to serving niche patient populations, particularly those with compromised immune systems.

Labcyte Inc., founded in 2000 and based in San Jose, California, specializes in developing acoustic droplet ejection (ADE) technology for various applications in the life sciences. The company's innovative approach uses focused beams of acoustic energy to precisely dispense nanoliter-scale droplets of fluid from one plate to another, enabling high accuracy at low volumes and reducing consumables costs. Labcyte's products include automation systems, laboratory workstations, and control software, which are utilized in drug discovery, genomics research, cancer research, and personalized medicine. The company operates as a subsidiary of Beckman Coulter, Inc., with additional offices across multiple countries including Canada, the United Kingdom, Australia, India, South Korea, China, Hong Kong, Japan, Singapore, and Taiwan.

Edgemont Pharmaceuticals is a developer of innovative drug formulations aimed at treating psychiatric disorders. The company focuses on creating novel therapies in the field of neuroscience, specifically targeting conditions such as major depressive disorder, bulimia nervosa, obsessive-compulsive disorder, and panic disorder. By advancing these new treatment options, Edgemont Pharmaceuticals seeks to provide effective solutions that help patients manage and overcome their depression and anxiety-related challenges. The company's leadership team brings extensive experience and a proven track record in the pharmaceutical industry and life sciences, underscoring its commitment to improving mental health outcomes.

Celula, Inc. is a diagnostic testing services company dedicated to enhancing the accuracy of diagnosing significant diseases, particularly focusing on women's health issues such as gynecologic cancers and non-invasive prenatal diagnosis. Founded in 2005 and headquartered in San Diego, California, with a development facility in Chengdu, China, Celula utilizes its Integrated Diagnostic Accuracy (IDA) platform, which combines both proprietary and non-proprietary technologies. This innovative approach aims to achieve higher diagnostic accuracy and reduce false positive rates, thereby improving patient care and clinical outcomes. The company delivers its test results through a customized Integrated Patient Report, which aids decision-making for patients and healthcare providers. By maintaining a robust infrastructure in the U.S. and China, Celula positions itself to develop cost-effective diagnostic solutions and expand its market opportunities.

ReShape Medical Inc. is a medical device company headquartered in San Clemente, California, specializing in non-surgical weight loss solutions. The company offers the ReShape Integrated Dual Balloon System, which employs dual balloon technology to aid weight loss in adults with a Body Mass Index (BMI) of 30-40 who have not achieved success with diet and exercise alone. This procedure is complemented by a personalized weight loss program that lasts one year. The company's product line includes the FDA-approved Lap-Band System, a minimally invasive treatment for obesity, and the investigational ReShape Vest System, designed to wrap around the stomach and induce weight loss without permanently altering patient anatomy. ReShape Medical's portfolio aims to provide effective alternatives to invasive surgical procedures for managing obesity and related metabolic diseases. The company operates as a subsidiary of EnteroMedics Inc., having undergone a name change in 2017.

Inhibrx, Inc. is a clinical-stage biotechnology company headquartered in La Jolla, California, that specializes in developing a diverse pipeline of novel biologic therapeutic candidates. The company's focus areas include oncology, orphan diseases, and infectious diseases, employing advanced protein engineering techniques, including its proprietary sdAb platform. Among its leading candidates is INBRX-109, a multivalent agonist of death receptor 5, currently in Phase 1 trials for treating solid tumors, including sarcomas. Another candidate, INBRX-105, serves as an antagonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB, also in Phase 1 trials for PD-L1 expressing tumors. Additional candidates include INBRX-101, aimed at alpha-1 antitrypsin deficiency, and INBRX-103, targeting cluster of differentiation 47. The company's preclinical programs encompass innovative therapies such as INBRX-106, a hexavalent agonist of OX40, and INBRX-111, a multifunctional antibody targeting Pseudomonas aeruginosa. Founded in 2010, Inhibrx has established collaborations with prominent organizations and received funding from various granting agencies.

InterValve Inc. is a medical device company specializing in the catheter-based treatment of calcified aortic valve stenosis. Founded in 2008 and located in Plymouth, Minnesota, the company develops innovative tools for both percutaneous and trans-apical aortic valve replacement procedures. One of its key products is the V8 Aortic Valvuloplasty Balloon Catheter, which represents a next-generation solution designed to improve treatment outcomes for patients with calcific aortic stenosis. This third-generation balloon catheter features a unique figure 8 shape that minimizes movement, optimizes the aortic valve area, and enhances leaflet hyperextension while reducing the risk of annulus over-distension. InterValve Inc. operates as a subsidiary of Venus MedTech (HangZhou) Inc.

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative treatments for central nervous system diseases. The company is advancing a diverse portfolio of product candidates, with its lead compound, roluperidone, currently in Phase III clinical trials for schizophrenia. Additionally, Minerva is developing seltorexant, which has completed Phase IIb trials for insomnia and major depressive disorders, and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein in pre-clinical trials aimed at treating Parkinson’s disease. Minerva has established strategic partnerships, including a licensing agreement with Mitsubishi Tanabe Pharma Corporation for roluperidone outside Asia, and a co-development agreement with Janssen Pharmaceutica for seltorexant. Originally founded in 2007 as Cyrenaic Pharmaceuticals, the company rebranded to Minerva Neurosciences in 2013 and is headquartered in Waltham, Massachusetts.

Asensus Surgical is a medical device company focused on enhancing minimally invasive surgery through digital laparoscopy. By digitizing the interface between surgeons and patients, the company incorporates advanced technologies such as augmented intelligence, connectivity, and robotics into surgical procedures. Their flagship product, the Senhance Surgical System, is notable for being the first machine vision system designed for robotic surgery. This system is supported by the Intelligent Surgical Unit, which facilitates augmented intelligence in surgery. Asensus Surgical aims to address various clinical, cognitive, and economic challenges faced in surgical practices, ultimately improving patient outcomes through innovative solutions in digital laparoscopy.

Trevena, Inc., founded in 2007 and headquartered in Chesterbrook, Pennsylvania, is a biopharmaceutical company dedicated to the development of innovative medicines for central nervous system (CNS) disorders. The company specializes in creating G protein-coupled receptor (GPCR) biased ligands, which aim to improve upon existing therapies by enhancing efficacy and reducing adverse effects. Trevena's pipeline includes several product candidates: Oliceridine injection, a mu-opioid receptor ligand completed Phase III trials for acute pain management; TRV250, a delta-opioid receptor agonist in Phase I study for migraine treatment; TRV734, a small molecule MOR ligand in Phase I study for acute and chronic pain; TRV027, currently in phase 2 clinical testing for the treatment of acute heart failure; and TRV045, an S1P modulator for managing chronic pain. Trevena has also collaborated with Imperial College London to evaluate Trv027 in Covid-19 patients.

Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.

HTG Molecular Diagnostics is a commercial-stage life sciences company based in Tucson, Arizona, specializing in precision medicine through its innovative HTG EdgeSeq platform. Established in 1997, the company offers a suite of molecular-based technology solutions for gene expression profiling and the measurement of various RNA types, including miRNA and mRNA. The HTG EdgeSeq technology automates sample processing, allowing for the rapid and simultaneous profiling of hundreds to thousands of molecular targets using minimal biological material. HTG Molecular Diagnostics markets a range of products, including instruments, assay kits, and software, which work together to facilitate efficient molecular profiling. Its offerings include several specialized panels designed for oncology and immuno-oncology applications. The company serves a diverse clientele comprising biopharmaceutical firms, academic research institutions, and molecular testing laboratories, distributing its products directly in the United States and Europe, as well as through international distributors.

diaDexus is a privately held biotechnology company based in the United States, specializing in the discovery, development, and commercialization of innovative diagnostic products with significant clinical relevance. The company's flagship product, the PLAC Test, assesses levels of Lp-PLA2, an enzyme linked to the formation of harmful plaque in blood vessels, which is a key factor in cardiovascular events like heart disease and stroke. The PLAC Test is unique as it is the only FDA-cleared blood test that aids in evaluating the risk for coronary heart disease and ischemic stroke related to atherosclerosis. In addition to cardiovascular diagnostics, diaDexus offers test kits for various conditions, including liver disease, cancer markers, renal disease, diabetes, and electrolyte imbalances. The company primarily operates in the United States, with a growing presence in Europe and other regions worldwide.